Key Takeaways for Pfizer Stock as of September 2026
- Spring Rebound: PFE stock is up 10% YTD, and most of that gain arrived after Pfizer’s August 4 EPS beat and $500M guidance raise sent shares from a $24 June low to $28.
- Earnings Beat: Q2 adjusted EPS reached $0.77 versus a $0.68 estimate, and Pfizer raised full-year revenue guidance by $500M to $60.5B-$62.5B.
- Target Lag: PFE stock carries 8 buy ratings, 2 outperforms, 16 holds, 1 underperform and 1 sell, while the Street’s ~$29 mean target (from 26 analysts) sits just 4% above the current price.
- Model Verdict: TIKR’s mid-case model targets $29, implying 4% total return and 1% annualized.
- Dividend Pledge: Bourla told analysts Pfizer would maintain and eventually grow its dividend even under the company’s most stretched internal scenarios, while cost-savings targets expanded to $9.7B in net savings through 2029.
Why Pfizer Stock’s 10% YTD Gain Traces to One August Earnings Beat
Pfizer (PFE) stock has climbed 10% since early January, and nearly all of that gain arrived in the ten weeks after the company’s August 4 earnings beat pulled shares up from a June low. The stock closed at $24 on June 28, its lowest print of the year, before climbing to $28 by September 8, a 14% jump inside a single quarter.
That reversal traces to one earnings call. Pfizer’s adjusted EPS came in at $0.77 against a $0.68 estimate, and the company raised its full-year revenue guidance by $500 million at the midpoint, to a range of $60.5 billion to $62.5 billion. CEO Albert Bourla framed the quarter as part of a longer pattern on the Q2 2026 call: “With our performance in the second quarter, this is the ninth time we exceeded consensus expectations for revenues in the last 10 quarters, and we have beaten expectations for adjusted diluted EPS in all 10 of the 10 past quarters.” That’s what the market paid up for: a company that keeps clearing the bar it sets for itself, not a new growth story.
Management also widened its cost-cutting math, lifting expected net savings from its productivity and manufacturing programs to $9.7 billion through 2029, and Bourla told analysts the dividend would hold even under the company’s most stretched internal scenarios. Both points carried extra weight this quarter, since Pfizer’s guidance absorbs a $0.10 EPS headwind from the newly closed Innovent Biologics oncology deal. The rally reads as a vote of confidence in execution and cash return, not in the top line growth debate still hanging over Pfizer stock ahead of its post-2028 patent cliff.
Pfizer Stock’s Rally Outran a Street That Barely Blinked
Pfizer stock carries 8 buy ratings, 2 outperforms, 16 holds, 1 underperform and 1 sell as of September 8. Separately, 26 analysts publish a price target, and their mean sits at $29, just 4% above the current price of $28.
That gap used to be much wider. On June 28, when the stock closed at $24, the same $29 mean target implied 20% upside, a Target/Close ratio of 120%. Analysts never chased the rebound. The stock did the work itself, climbing 14% in ten weeks while the Street’s dollar target barely moved.
Coverage held roughly steady across the year, swinging between 21 and 27 analysts publishing a target, and the buy-rating count actually crept higher, from 7 analysts in mid-2025 to as many as 9 in June, even as the price target stayed anchored near $29.
TIKR Values Pfizer Stock at $29, a Thin Premium to Today’s Price
TIKR’s mid-case model values Pfizer stock at $29 by December 2030, implying a 4% total return from the current price of $28, or 1% annualized over 4.3 years.
That projected 1% annual return sits well below what investors typically expect from a large-cap pharmaceutical holding, and it signals TIKR’s model reads Pfizer stock as fairly valued rather than cheap after this year’s climb.
That gap looks even wider next to Pfizer’s own numbers. The stock’s forward dividend yield sits at 6%, down from 7% back on June 28, which means most of TIKR’s projected return comes from the payout itself, not from price appreciation
The thin premium lines up with what the Street already shows. Analysts left their mean target anchored near $29 through the entire round trip from $24 to $28, and TIKR’s own model, built on a longer 2030 horizon, arrives at almost the same number. Both readings say the same thing: the August earnings beat earned Pfizer stock its way back into its prior range, not a re-rating beyond it.
Should You Invest in Pfizer Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Pfizer Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Pfizer Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze PFE stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
